San Diego, CA -- (SBWIRE) -- 01/13/2017 -- An investigation on behalf of investors of Pacific Biosciences of California (NASDAQ:PACB) shares over potential securities laws violations in connection certain financial statements was announced.

Investors who purchased shares of Pacific Biosciences of California (NASDAQ:PACB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements regarding Pacific Biosciences of California's business, its prospects and its operations were materially false and misleading at the time they were made.

Pacific Biosciences of California reported that its annual Total Revenue rose from $60.59 million in 2014 to $92.78 million in 2015 and that its Net Loss declined from $66.16 million in 2014 to $31.70 million in 2015.

Shares of Pacific Biosciences of California (NASDAQ:PACB) rose to as high as $13.24 per share in late December 2015.

On Decmeber 15, 2016, Pacific Biosciences of California, Inc. (Nasdaq:PACB) announced that F. Hoffman-La Roche Ltd (Roche) has elected to terminate for convenience the development, commercialization and license agreement with Pacific Biosciences for the development and supply of diagnostic products based on the company's Single Molecule, Real-Time (SMRT®) technology.

Shares of Pacific Biosciences of California (NASDAQ:PACB) declined to as low as $3.76 per share in late December 2016.

On January 12, 2017, NASDAQ:PACB shares closed at $4.69 per share.

Those who purchased shares of Pacific Biosciences of California have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com